Pfizer predicts sales in 2024 could be $5bn below Wall Street expectations, sending shares to a 10-year low. Revenue from Pfizer’s COVID-19 vaccine and treatment, which peaked at $57bn in 2022, is now expected to be $8bn in 2024, a further decline from analysts’ $13bn forecast.